Skip to main content

Table 1 Demographics and outcomes of the ICU population and a comparison between the sepsis and non-sepsis cohorts

From: Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness

  ICU population Sepsis cohort Non-sepsis cohort p value
Number, n (% of ICU population) 1867 (100) 632 (33.9) 1235 (66.1)  
Age in years, median (IQR) 67 (54–75) 69 (61–76) 65 (49.5–73) < 0.001
Female sex, n (%) 738 (39.5) 251 (39.7) 487 (39.4) 0.95
Department of origin
Emergency department/out of hospital, n (%) 896 (48) 276 (43.7) 620 (50.2) 0.008
Hospital ward, n (%) 604 (32.4) 282 (44.6) 322 (26.1) < 0.001
Intermediate, n (%) 50 (2.7) 32 (5.1) 18 (1.5) < 0.001
Operating room/postoperative ward, n (%) 317 (17) 42 (6.6) 275 (22.3) < 0.001
Organ dysfunction and illness severity on ICU admission
SAPS3 score, median (IQR) 59 (47–71) 66 (57–77) 54 (43–67) < 0.001
SAPS3 EMR30-day, median (IQR) 17.6 (5.2–40.3) 29.9 (14.8–53) 11.1 (3.1–31.9) < 0.001
SOFA score, median (IQR) 6 (3–9) 7 (5–10) 4 (1–8) < 0.001
Cardiovascular SOFA score (n = 1836), median (IQR) 1 (0–3) 3 (0–4) 1 (0–3) < 0.001
Outcomes
ICU mortality, n (%) 208 (11.1) 86 (13.6) 122 (9.9) 0.019
30-day mortality, n (%) 402 (21.5) 174 (27.5) 228 (18.5) < 0.001
1-year mortality, n (%) 622 (33.3) 261 (41.3) 361 (29.2) < 0.001
ICU length of stay in days, median (IQR) 1.6 (0.8–3.6) 2.5 (1.1–5.5) 1.1 (0.7–2.7) < 0.001
CRRT use during ICU stay, n (%) 169 (9) 96 (15.2) 73 (5.9) < 0.001
bio-ADM
bio-ADM pg/mL, median (IQR) 40 (21–86) 74 (42–145) 29 (18–56) < 0.001
bio-ADM> 70 pg/mL, n (%) 564 (30.2) 333 (52.7) 231 (18.7) < 0.001
  1. Data regarding general characteristics, outcomes, organ dysfunction and illness severity are presented. The sepsis cohort was compared to the non-sepsis cohort, and the p values refer to that comparison. Proportions (%) are within their subgroups unless otherwise specified. ICU: intensive care unit; IQR: interquartile range; SAPS3: Simplified Acute Physiology Score III; EMR30-day: estimated 30-day mortality risk; SOFA: Sequential Organ Failure Assessment; CRRT: continuous renal replacement therapy; bio-ADM: circulating bioactive adrenomedullin